Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 131 resultados

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

LateFun: Late stage photocatalytic functionalization of alkenes and 1 3 dienes NOVARTIS PHARMA AG participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 The late-stage functionalization (LSF) of bioactive compounds is currently a hot topic in the chemistry community, as it allows for the rapi...
2024-03-13 - 2027-08-31 | Financiado

Chiral-Beta: Asymmetric carbyne catalytic transfer to streamline synthesis of chiral amino carbonyls NOVARTIS PHARMA AG participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 The chiral β-amino carbonyl is an important structural motif prevalent in natural products and therapeutic agents. Despite that many methodo...
2024-03-01 - 2026-12-31 | Financiado

EPND: European platform for neurodegenerative disorders NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a la...
2021-10-25 - 2026-10-31 | Financiado

SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado

HIPPOCRATES: Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging a...
2021-06-29 - 2026-06-30 | Financiado

BIGPICTURE: Central Repository for Digital Pathology NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

Gravitate-Health: Gravitate Health Empowering and Equipping Europeans with health information for Active Personal Hea... The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsiv...
2020-11-12 - 2025-10-31 | Financiado

ARDAT: Accelerating Research Development for Advanced Therapies NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado

H2O: H2O Health Outcomes Observatory NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Patients' outcomes and experience of health care can be improved through the systematic capture and use of information from their perspectiv...
2020-09-30 - 2025-09-30 | Financiado

CARE: Corona Accelerated R D in Europe NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in thi...
2020-08-07 - 2025-03-31 | Financiado

PREMIER: Prioritisation and Risk Evaluation of Medicines in the EnviRonment NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has b...
2020-06-24 - 2026-08-31 | Financiado

CHAIR: C H Activation for Industrial Renewal NOVARTIS PHARMA AG participó en un H2020: H2020-MSCA-ITN-2019 C-H activation is one of the most rapidly expanding areas of molecular chemistry and has emerged as an increasingly viable tool. Despite cle...
2020-06-22 - 2024-12-31 | Financiado

HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado

INNODIA HARVEST: Translational approaches to disease modifying therapy of type 1 diabetes HARVESTing the fruits of... NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diab...
2020-04-16 - 2024-04-30 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado

PharmaLedger: PharmaLedger NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the...
2019-12-16 - 2022-12-31 | Financiado

EU-PEARL: EU Patient cEntric clinicAl tRial pLatform NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company I...
2019-11-27 - 2023-04-30 | Financiado

imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado

Immune-Image: Immune Image Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies NOVARTIS PHARMA AG participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although...
2019-09-26 - 2026-03-31 | Financiado